Mittie Doyle - 16 Mar 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role
Chief Medical Officer
Signature
/s/ Christopher Sullivan, Attorney-in-Fact
Issuer symbol
AVTX
Transactions as of
16 Mar 2026
Net transactions value
-$411,607
Form type
4
Filing time
18 Mar 2026, 16:07:19 UTC
Previous filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Doyle Mittie Chief Medical Officer C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE /s/ Christopher Sullivan, Attorney-in-Fact 18 Mar 2026 0001918845

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTX Common Stock Options Exercise +19,500 +538% $12.65* 23,122 16 Mar 2026 Direct
transaction AVTX Common Stock Options Exercise +5,992 +26% $8.04* 29,114 16 Mar 2026 Direct
transaction AVTX Common Stock Sale $411,607 -25,492 -88% $16.15 3,622 16 Mar 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTX Stock Option (Right to Buy) Options Exercise -19,500 -8.3% $0.000000* 214,500 16 Mar 2026 Common Stock 19,500 $12.65 Direct F2
transaction AVTX Stock Option (Right to Buy) Options Exercise -5,992 -3.9% $0.000000* 149,008 16 Mar 2026 Common Stock 5,992 $8.04 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported securities were sold in multiple transactions at prices ranging from $16.00 to $16.34. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2 The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
F3 The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.